EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen, He Wang, Jun Dang

International Journal of Radiation Oncology*Biology*Physics · 2024-07 · 119 (4) · 1179-1207

DOI: 10.1016/j.ijrobp.2024.01.217 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-07. Verfasst von Chong Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Pneumonia. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 191 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors (ICIs) is the standard of care for patients with unresectable and locally advanced non-small cell lung cancer. This study aimed to determine whether the addition of ICIs to CRT is associated with an increased risk of pneumonitis. METHODS AND MATERIALS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published between January 1, 2015, and July 31, 2023. The outcome of interest was the incidence rate of pneumonitis. A random-effects model was used for statistical analysis. RESULTS: A total of 185 studies with 24,527 patients were included. The pooled rate of grade ≥2 pneumonitis for CRT plus ICIs was significantly higher than that for CRT alone (29.6%; 95% CI, 25.7%-33.6% vs 20.2%; 95% CI, 17.7%-22.8%; P < .0001) but not that of grade ≥3 (5.7%; 95% CI, 4.8%-6.6% vs 5.6%; 95% CI, 4.7%-6.5%; P = .64) or grade 5 (0.1%; 95% CI, 0.0%-0.2% vs 0.3%; 95% CI, 0.1%-0.4%; P = .68). The results from the subgroup analyses of prospective studies, retrospective studies, Asian and non-Asian studies, concurrent CRT (cCRT), and durvalumab consolidation were comparable to the overall results. However, CRT or cCRT plus PD-1 inhibitors not only significantly increased the incidence of grade ≥2 but also that of grade ≥3 pneumonitis compared to CRT alone or cCRT plus PD-L1 inhibitors. CONCLUSIONS: Compared with CRT alone, durvalumab consolidation after CRT appears to be associated with a higher incidence of moderate pneumonitis and CRT plus PD-1 inhibitors with an increased risk of severe pneumonitis. Nevertheless, these findings are based on observational studies and need to be validated in future large head-to-head studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyPneumoniaImmune Checkpoint InhibitorsImmunotherapyHumansIncidenceRisk

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, China.
  • Department of Radiation Oncology, Anshan Cancer Hospital, Anshan, China.
  • Department of Radiation Oncology, Shenyang Tenth People's Hospital, Shenyang, China.
  • Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, China. Electronic address: dangjunsy@163.com.

Zitieren

APA

Han, C., Qiu, J., Bai, L., Liu, T., Chen, J., Wang, H., & Dang, J. (2024). Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics, 119(4), 1179-1207. https://doi.org/10.1016/j.ijrobp.2024.01.217

Vancouver

Han C, Qiu J, Bai L, Liu T, Chen J, Wang H, et al. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics. 2024;119(4):1179-1207. doi:10.1016/j.ijrobp.2024.01.217

BibTeX
@article{Han2024,
  author = {Han, Chong and Qiu, Jingping and Bai, Lu and Liu, Tingting and Chen, Jun and Wang, He and Dang, Jun},
  title = {Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  volume = {119},
  number = {4},
  pages = {1179--1207},
  doi = {10.1016/j.ijrobp.2024.01.217}
}
Kostenlos starten →